The observations in IL-10−/− mice led to therapeutic trials of IL-10 in other models of colitis, showing that systemic IL-10 administration can prevent intestinal inflammation by down regulating the intestinal pro-inflammatory Th1 response [92,97,98]. This evidence concerns the gene IL10 and colitis.